High materiality8/10
Vertex Pharmaceuticals price target raised to $585 from $545 at UBS
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
UBS raises VRTX target to $585 from $545; current price $481.70; upside potential remains to target.
- Target: $585 (from $545)
- Price: $481.70
- Upside to target
Key facts
- 01
Target: $585
- 02
Posted price: $481.7
- 03
Analyst firm: UBS
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.